Comparison of silver-coated dressing (Acticoat), chlorhexidine acetate 0.5% (Bactigrass), and silver sulfadiazine 1% (Silverdin) for topical antibacterial effect in Pseudomonas aeruginosa-contaminated, full-skin thickness burn wounds in rats.
Acticoat (Smith and Nephew, Istanbul, Turkey), chlorhexidine acetate 0.5%, and silver sulfadiazine 1% were compared to assess the antibacterial effect of their application on experimental burn wounds in contaminated with Pseudomonas aeruginosa in rats. All treatment modalities were effective against P. aeruginosa because there were significant differences between treatment groups and control groups. The mean eschar concentrations did not differ significantly between Acticoat and chlorhexidine acetate groups, but there were significant differences between the silver sulfadiazine group and the other treatment groups, indicating that silver sulfadiazine significantly eliminated P. aeruginosa more effectively in the tissues than did the other two agents. All treatment modalities were sufficient to prevent the P. aeruginosa from invading to the muscle and from causing systemic infection. In conclusion, silver sulfadiazine is the most effective agent in the treatment of the P. aeruginosa-contaminated burn wounds; Acticoat can be considered as a treatment choice because of its peculiar ability of limiting the frequency of replacing wound dressings.
Ulkür
Ersin
E
GATA Haydarpasa Training Hospital, Istanbul,Turkey.
Oncül
Oral
O
Karagöz
Hüseyin
H
Celiköz
Bahattin
B
Cavuşlu
Saban
S
D000287:Administration, Topical; D000818:Animals; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001458:Bandages; D002056:Burns / Q000150:complications / Q000382:microbiology*; D002710:Chlorhexidine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D011091:Polyesters / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011095:Polyethylenes / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa / Q000472:pathogenicity; D051381:Rats; D017208:Rats, Wistar; D012837:Silver Sulfadiazine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
C117408:Acticoat; D000891:Anti-Infective Agents, Local; D011091:Polyesters; D011095:Polyethylenes; D002710:Chlorhexidine; D012837:Silver Sulfadiazine